Investor Presentaiton
R&D investor presentation
36
In STEP 4, 41.2% of patients treated with semaglutide reached ≥20%
weight loss and reported improved quality of life versus placebo
Sema 2.4 mg showed a statistically significant treatment
difference versus placebo in the SF-36 patient reported outcome
Categorical weight loss
Proportion of
patients
SF-36 scores
100%
| 90.5%
■Sema 2.4 mg
■ Placebo
Physical functioning
80.8%
Role-physical
80%
65.5%
60%
50.0%
40%
20%
41.2%
20.9%
9.8%
5.1%
0%
≥5%
≥10%
Weight loss
≥15%
≥20%
Descriptive statistics only. Based on the on-treatment data, i.e. data for subjects that are on-
treatment at week 68
Sema: semaglutide
Bodily pain
General health
Vitality
Social functioning
Role-emotional
Mental health
Physical component summary
Mental component summary
Favours placebo
Favours semaglutide
ETD [95% CI]
*
2.46 [1.59 3.32]
1.44 [0.42 2.47] *
2.23 [-0.06 4.53]
1.86 [0.73 3.00]
*
4.31 [1.61
2.41 [0.07
:
7.02] *
4.76] *
1.64 [0.52 2.76]
2.93 [1.80 4.06]
1.68 [0.64 2.72] *
3.44 [2.28 4.60]
*
*
*
-1 0 1 2 3 4 5 6 7 8
* statistically significant; p-values other than physical functioning were not controlled for multiplicity
CI: confidence interval, ETD: estimated treatment difference, Sema: semaglutide, SF-36: Short Form (36) Health
SurveyView entire presentation